Who Paid My Doc
Mark Fung
Blood Banking & Transfusion Medicine Burlington, VT Medical Doctor
NPI 1043245657 CMS profile 734843
111 Colchester Ave, Fletcher Allen Health Care - Pathology, Burlington, VT 05401
General payments
$46,743
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Mark Fung of Burlington, VT is reported in the CMS Open Payments database as having received $46,743 across 50 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 89th percentile of Blood Banking & Transfusion Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $7,800 | 3 | |
| 2023 | General | $4,450 | 3 | |
| 2022 | General | $4,450 | 2 | |
| 2021 | General | $3,150 | 1 | |
| 2020 | General | $2,500 | 2 | |
| 2019 | General | $24,393 | 39 |
Beside peers
- Mark Fung
- Blood Banking & Transfusion Medicine median
- Middle half of Blood Banking & Transfusion Medicine
- National median
In program year 2025, general payments to Mark Fung were reported at $0. Among 109 Blood Banking & Transfusion Medicine profiles paid that year, the median was $146 and the middle half received between $63 and $2,018.
Show as a table
| Year | Mark Fung | Blood Banking & Transfusion Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $24,393 | $125 | $48–$2,312 | $163 |
| 2020 | $2,500 | $759 | $90–$20,131 | $114 |
| 2021 | $3,150 | $1,000 | $95–$13,211 | $132 |
| 2022 | $4,450 | $260 | $66–$4,567 | $149 |
| 2023 | $4,450 | $201 | $62–$2,687 | $160 |
| 2024 | $7,800 | $150 | $42–$2,468 | $164 |
| 2025 | $0 | $146 | $63–$2,018 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$12,409
Medicare patients
738
Services billed
979
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Arthritis | 46% | |
| Chronic kidney disease | 33% | |
| Diabetes | 29% | |
| Ischemic heart disease | 29% | |
| Atrial fibrillation | 23% | |
| Heart failure | 22% | |
| Depression | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
50 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Blood Banking & Transfusion Medicine in Vermont
Practitioners in the same specialty and state, ranked by reported value.
All Blood Banking & Transfusion Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Vermont
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.